Trever Todd
About Trever Todd
Trever Todd is a Senior Clinical Scientist at Arcus Biosciences, where he has worked since 2020. He holds a Ph.D. in Analytical Chemistry/Nanotechnology from The University of Georgia and has extensive experience in clinical trials for solid tumors, particularly in lung cancer.
Work at Arcus Biosciences
Trever Todd serves as a Senior Clinical Scientist at Arcus Biosciences since 2020. In this role, he focuses on the design and execution of clinical trials, particularly those involving immune checkpoint inhibitors. His work includes leading trials that target specific patient populations, such as those with post-TKI progression in mEGFR lung cancer. Todd's expertise contributes to the advancement of treatment options in oncology, particularly in solid tumors.
Education and Expertise
Trever Todd earned a Doctor of Philosophy (Ph.D.) in Analytical Chemistry and Nanotechnology from The University of Georgia, where he studied from 2011 to 2016. He also holds a Bachelor of Science (B.S.) in Chemistry from Armstrong Atlantic State University, completed in 2010. His educational background provides a strong foundation for his work in clinical science, particularly in the development and monitoring of clinical trials.
Background
Before joining Arcus Biosciences, Trever Todd worked at Allergan as a Clinical Scientist from 2019 to 2020 and as a USC-Allergan Drug Delivery Fellow from 2017 to 2018. His earlier experience includes serving as a Graduate Research Assistant at the University of Georgia from 2011 to 2016. This diverse background in both academic and industry settings has equipped him with a comprehensive understanding of clinical research processes.
Achievements
Trever Todd has developed extensive experience in clinical trials, particularly those involving immune checkpoint inhibitors. He has worked on combinations of PD-1 with chemotherapy and PD-1 with TIGIT. His focus on solid tumors includes significant contributions to trials for ICI NSCLC and EGFRm NSCLC. Todd leads initiatives that address the needs of mEGFR lung cancer patients, particularly in the context of post-TKI progression.